The US Food and Drug Administration (FDA) has announced a significant push towards the integration of artificial intelligence in its drug evaluation processes. The agency has completed the first pilot of AI-assisted scientific reviews and set an aggressive timeline for internal deployment of AI technologies across its various centers by June 2025. As part of this initiative, the FDA has appointed its first-ever chief AI officer, emphasizing the importance of AI in expediting drug reviews. The FDA is also in discussions with OpenAI about leveraging AI for more efficient drug evaluations, aiming to potentially shorten the drug approval process. The agency is planning to deploy AI assistants for research reviews by the end of June, marking a transformative step in enhancing the efficacy of its operations.